FDA label 6C732EA7-0BA6-D980-CCC0-E5045B674863

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

SPL set ID
B503FA5E-5726-426D-867C-E8FE59ED3EAD
SPL ID
6C732EA7-0BA6-D980-CCC0-E5045B674863
Version
2
Effective date
2006-02-06
Source export date
2026-11-13
Source partition
1
Source file
https://download.open.fda.gov/drug/label/drug-label-0001-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/4245fd4310917b72c4a58c789d30a0b365e492ef46f48e107e3c3e16139b0499/drug-label-0001-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 15:23:57

Boxed warning cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Boxed warning sections page 1 of 1 · 1 matching rows.

boxed warning

WARNING This fixed combination drug is not indicated for initial therapy of hypertension. Hypertension requires therapy titrated to the individual patient. If the fixed combination represents the dosage so determined, its use may be more convenient in patient management. The treatment of hypertension is not static, but must be reevaluated as conditions in each patient warrant.

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

WARNINGS Serum electrolyte determinations are especially indicated for patients with severe derangement of metabolic processes, e.g., surgery, vomiting, or parenteral fluid therapy. Electrolyte imbalance may be caused by certain diseases such as cirrhosis, or it may result from drug therapy, such as therapy with corticosteroids. Patients with cirrhosis who are continually receiving RENESE-R should be observed carefully for the development of hepatic precoma or coma. Indications of impending hepatic failure are tremor, confusion, drowsiness, and hepatic fetor. Thiazides may precipitate kidney failure and uremia in patients with pre-existing renal pathology and impaired renal function. Available information tends to implicate all oral dosage forms of potassium salts ingested in solid form with or without thiazides in the etiology of nonspecific, small bowel lesions consisting of ulceration with or without stenosis, causing obstruction, hemorrhage and perforation, and frequently requiring surgery. Deaths due to these complications have been reported. All oral dosage forms of potassium salts ingested in solid form should be used only when adequate dietary supplementation is not practical, and should be discontinued immediately if abdominal pain, distention, nausea, vomiting, or gastrointestinal bleeding occur. RENESE-R does not itself contain enteric-coated potassium. Electroshock therapy should not be given within one week of cessation of reserpine. Reserpine may cause mental depression. Recognition of depression may be difficult because this condition may often be disguised by somatic complaints (Masked Depression). The drug should be discontinued at first signs of depression such as despondency, early morning insomnia, loss of appetite, impotence, or self-deprecation. Drug-induced depression may persist for several months after drug withdrawal and may be severe enough to result in suicide.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 1 matching rows.

adverse reactions

ADVERSE REACTIONS The following adverse reactions have been observed, but there is not enough systemic collection of data to support an estimate of their frequency. Polythiazide The most common reactions associated with polythiazide therapy are weakness and dizziness, but seldom require cessation of therapy. Weakness is reported in less than 3% of patients receiving the drug, and dizziness is reported in less than 2% of patients. These can be overcome by reducing the dose or taking measures to improve electrolytic balance. Other reactions, reported to occur in less than 1% of patients, are: Gastrointestinal: nausea, gastrointestinal disturbances, reversible cholestatic jaundice, necrotizing angiitis, pancreatitis. Dermatological: maculopapular skin rash, photosensitivity. Central Nervous System: vertigo, paresthesia, fatigue, headache. Cardiovascular: orthostatic hypotension. EENT: xanthopsia. Hematological: Leukopenia (neutropenia), agranulocytosis, and aplastic anemia have been reported with the older thiazides but not with the newer compounds such as polythiazide. Purpura (with or without thrombocytopenia) has been reported with polythiazide. Reserpine The most common reactions associated with reserpine therapy, dizziness and drowsiness, are reported in less than 2% of patients. Reactions to reserpine are usually reversible and disappear when the drug is discontinued. Other reactions, occurring in less than 1% of patients on reserpine are: Gastrointestinal: hypersecretion, nausea, vomiting, diarrhea, anorexia, dry mouth. Dermatological: rash, pruritus, purpura. Central Nervous System: depression, nervousness, paradoxical anxiety, nightmares, headache, and rare Parkinsonian syndrome to CNS sensitization manifested by deafness, glaucoma, uveitis, and optic atrophy. Cardiovascular: angina-like symptoms, arrhythmias particularly when used concurrently with digitalis or quinidine, flushing of the skin, and bradycardia. EENT: nasal congestion, miosis. Sexual Difficulties: impotence or decreased libido.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.